Waypoint Wealth Counsel’s United Therapeutics UTHR Stock Holding History

Waypoint Wealth Counsel’s Portfolio UTHR Stock Details UTHR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-372	Closed	-$221K	–	237
2026 Q1	$221K	Sell	372 -329	-47%	-$164K	0.11%	198
2025 Q4	$342K	Buy	+701	New	+$326K	0.13%	170

Other funds holding UTHR

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Jupiter Topco New York $245B AUM

Norges Bank Oslo, Norway $1T AUM

Waypoint Wealth Counsel's UTHR Position: Q2 2026 in Review

Waypoint Wealth Counsel sold out of United Therapeutics (UTHR) in Q2 2026, closing a stake of 372 shares — an estimated $221K sold.

Waypoint Wealth Counsel first reported a position in UTHR in Q4 2025 and held it in 2 quarters. The position peaked at $342K in Q4 2025. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

Waypoint Wealth Counsel reported no remaining United Therapeutics position as of Q2 2026 after selling out during the quarter.
Waypoint Wealth Counsel sold 372 United Therapeutics shares in Q2 2026, an estimated $221K.
Waypoint Wealth Counsel first reported a position in United Therapeutics in Q4 2025 and held it in 2 quarters.
Waypoint Wealth Counsel's United Therapeutics position peaked at $342K in Q4 2025.
880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Waypoint Wealth Counsel's 13F filing for Q2 2026, filed 4 Aug 2026.